LACTOLOGY FOUNDATION

Methylscopolamine (ATC A03BB03) is a quaternary ammonium antimuscarinic used as an adjunct in peptic ulcer disease and functional gastrointestinal disorders, with additional use as a drying agent for secretions; breastfeeding data are lacking, so risk–benefit assessment and preference for better-characterized alternatives are advisable, especially for systemic use.medpedia.framar+3

ATC Class A03BB03 Overview

A03BB03 comprises methylscopolamine (methscopolamine), a semisynthetic quaternary ammonium derivative of scopolamine belonging to the subgroup “belladonna alkaloids, semisynthetic, quaternary ammonium compounds.”drugbank+2
It is classified under “Drugs for functional gastrointestinal disorders” and more specifically under “Belladonna alkaloids, semisynthetic, quaternary ammonium compounds, plain.”wikipedia+1

Methylscopolamine is usually marketed as the bromide salt (methscopolamine bromide) and, less commonly, as the nitrate salt.drugbank+1
Oral formulations are typically used in combination with other agents rather than as monotherapy.wikipedia+1

Mechanism of Action

Methylscopolamine is a competitive antagonist at muscarinic acetylcholine receptors, inhibiting parasympathetic activity in smooth muscle, exocrine glands, and to a lesser extent the central nervous system.ncbi.nlm.nih+2
The quaternary ammonium structure limits its penetration across the blood–brain barrier relative to tertiary amines such as atropine or scopolamine.ncbi.nlm.nih+1

By blocking muscarinic receptors, methylscopolamine reduces gastrointestinal motility and secretions, including gastric acid output.synapse.patsnap+2
Antimuscarinic effects on exocrine glands also decrease salivary and respiratory secretions, which underlies its use as an antisialagogue and drying agent.synapse.patsnap+2

Therapeutic Indications

Historically, methylscopolamine has been used as adjunctive therapy in peptic ulcer disease to decrease acid secretion and reduce recurrence and complications.dailymed.nlm.nih+3
Modern acid-suppressive therapies (proton pump inhibitors, H2-antagonists) have largely superseded this indication in routine practice.wikipedia

Additional indications include symptomatic treatment of gastrointestinal spasms and hypermotility, reduction of salivary and respiratory secretions, and use as a drying agent in upper airway conditions.prescriberpoint+2
Methscopolamine has also been included in some combination products for motion sickness and allergic conditions, although these uses are less common.prescriberpoint+1

Pharmacokinetics and Dynamics

Orally administered methylscopolamine has limited systemic absorption due to its quaternary ammonium structure, but sufficient levels are achieved to exert peripheral antimuscarinic effects.dailymed.nlm.nih+2
The onset of action for gastrointestinal indications is typically within a few hours, with dosing commonly scheduled before meals and at bedtime.synapse.patsnap+2

Because of reduced lipid solubility, central nervous system penetration is lower than with tertiary anticholinergics; however, CNS adverse effects can still occur at higher doses or in susceptible individuals.pediatriconcall+2
Renal excretion is the predominant elimination route, so accumulation may occur in severe renal impairment.drugbank+1

Dosage and Administration

Methscopolamine bromide tablets are commonly dosed at 2.5 mg orally 30 minutes before meals and 2.5–5 mg at bedtime, with a typical total daily dose around 12.5 mg for peptic ulcer adjunctive therapy.prescriberpoint+1
In patients needing rapid symptom relief from severe abdominal pain or cramping, initial daily doses up to 20 mg divided (e.g., 5 mg before meals and at bedtime) have been described, followed by down-titration according to response and tolerability.dailymed.nlm.nih+1

Dose adjustments should be considered in elderly, frail, or anticholinergic-sensitive patients, and therapy duration should be kept as short as compatible with clinical goals.ncbi.nlm.nih+1
Parenteral or ophthalmic formulations of related anticholinergics carry additional risks (e.g., acute angle-closure glaucoma) that are relevant by class analogy when considering patients with predisposing ocular disease.semanticscholar+1

General Toxicology

Acute toxicity of methylscopolamine is dominated by exaggerated antimuscarinic effects: dry mouth, mydriasis, tachycardia, urinary retention, decreased sweating, hyperthermia, ileus, and CNS disturbances.pediatriconcall+3
Because it is a quaternary compound, severe central toxicity (e.g., delirium) is less frequent than with tertiary anticholinergics but remains possible, especially at higher doses or in children.pubmed.ncbi.nlm.nih+1

Overdosage management is supportive and includes decontamination (e.g., induction of emesis where appropriate) and administration of physostigmine 0.5–2 mg intravenously, repeated up to a cumulative 5 mg as needed, plus temperature control measures.dailymed.nlm.nih
Patients with pre-existing glaucoma, prostatic hypertrophy, or obstructive gastrointestinal disease are at particular risk of serious complications from anticholinergic toxicity.prescriberpoint+1

Organ System Adverse Effects

Documented adverse effects encompass multiple organ systems, largely reflecting muscarinic blockade.pediatriconcall+2

·        Cardiovascular: Tachycardia and palpitations are common, particularly at higher doses or in patients with underlying cardiovascular disease.pediatriconcall+2

·        Central nervous system: Headache, nervousness, mental confusion, drowsiness, dizziness, and insomnia have been reported, with more severe CNS reactions linked to anticholinergic use in susceptible populations.pubmed.ncbi.nlm.nih+2

·        Ophthalmic: Blurred vision, mydriasis, cycloplegia, and increased intraocular pressure may occur, with a risk of precipitating acute angle-closure glaucoma in predisposed individuals.semanticscholar+3

·        Gastrointestinal: Nausea, vomiting, constipation, bloating, and even paralytic ileus can result from suppressed gastrointestinal motility.prescriberpoint+2

·        Genitourinary: Urinary hesitancy and retention are notable, particularly in elderly men with bladder outlet obstruction.pediatriconcall+1

·        Dermatologic and thermoregulatory: Decreased sweating, urticaria, and other skin manifestations can occur, and reduced sweating predisposes to hyperthermia, especially in hot environments.dailymed.nlm.nih+1

Contraindications and Precautions

Methscopolamine is contraindicated in glaucoma, obstructive uropathy (e.g., prostatic hypertrophy), obstructive gastrointestinal disease, paralytic ileus, intestinal atony in elderly or debilitated patients, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon, and myasthenia gravis.prescriberpoint+1
Hypersensitivity to methscopolamine or related anticholinergics is also a contraindication.dailymed.nlm.nih+1

Caution is required in patients with cardiovascular disease, autonomic neuropathy, hyperthyroidism, or conditions predisposing to urinary or bowel obstruction.ncbi.nlm.nih+2
In pediatric and geriatric populations, heightened sensitivity to anticholinergic effects necessitates conservative dosing and close monitoring.pubmed.ncbi.nlm.nih+1

Drug Interactions

Methylscopolamine exhibits additive anticholinergic effects when coadministered with other antimuscarinic agents (e.g., tricyclic antidepressants, first-generation antihistamines, antipsychotics, antiparkinsonian agents), increasing the risk of cumulative toxicity.ncbi.nlm.nih+2
Concurrent use with other drugs that slow gastrointestinal motility can further increase the risk of ileus and constipation.ncbi.nlm.nih+1

Combination with agents that elevate intraocular pressure may enhance the risk of precipitating glaucoma, particularly in patients with narrow angles.semanticscholar+1
Interactions with CNS depressants can potentiate sedation and cognitive impairment, although direct evidence for methscopolamine is extrapolated from the anticholinergic class.ncbi.nlm.nih+1

Lactation: Exposure and Risk Assessment

Specific pharmacokinetic data on methylscopolamine transfer into human milk are lacking, and major lactation references (e.g., LactMed for scopolamine) highlight limited evidence even for related compounds.ncbi.nlm.nih
As a quaternary ammonium compound with limited lipid solubility, extensive passage into milk and significant infant exposure are theoretically less likely than with tertiary amines; however, this cannot be assumed in the absence of direct measurements.ncbi.nlm.nih+2

General breastfeeding guidance emphasizes that most medications are compatible with lactation and that decisions should weigh maternal benefit against potential infant risk, considering infant age, health, and the extent of milk intake.breastfeedingnetwork+2
In the context of methylscopolamine, a key concern is the potential for anticholinergic effects in the nursing infant (e.g., constipation, urinary retention, decreased sweating, tachycardia), particularly with repeated systemic dosing.pediatriconcall+2

Given documented suppression of lactation with methscopolamine and related anticholinergics, there is also a risk of reduced milk production, especially early postpartum or in mothers with borderline supply.ncbi.nlm.nih+2
This effect on milk production is clinically significant even if direct infant exposure is modest, because decreased supply can compromise breastfeeding success.kellymom+1

Clinical Lactation Recommendations

·        Systemic therapy: In breastfeeding women, systemic methylscopolamine should generally be avoided when safer and better-studied alternatives exist for peptic ulcer disease or gastrointestinal disorders (e.g., PPIs, H2-antagonists, non-anticholinergic antispasmodics).cdc+2
If use is considered essential, it should be at the lowest effective dose, for the shortest duration, with monitoring for infant anticholinergic signs (poor feeding, constipation, decreased urine output, excessive drowsiness) and for maternal milk supply.kellymom+3

·        Local/short-term use: Brief, low-dose use (e.g., perioperative drying agent or occasional use in combination products) is less likely to cause clinically relevant infant exposure, particularly in older infants receiving complementary foods.breastfeedingnetwork+2
Even in such scenarios, caution is advised in neonates, premature infants, and infants with comorbidities, where any anticholinergic exposure may be less well tolerated.cdc+2

In mothers with established lactation and older infants, occasional low-dose exposure may be acceptable with informed consent and symptom-based infant monitoring, but data gaps mean that this remains a case-by-case decision.breastfeedingnetwork+3
When possible, choosing agents with explicit lactation safety data is preferred, especially for chronic indications.kellymom+2

Practical Counseling Points for Breastfeeding Mothers

Healthcare professionals should discuss the limited evidence base and explain that methylscopolamine belongs to a class known to reduce secretions and potentially suppress milk production.ncbi.nlm.nih+3
Mothers should be advised to monitor the infant for decreased stool frequency, reduced urine output, unusual lethargy, or feeding difficulties and to seek prompt evaluation if these occur.cdc+1

If a breastfeeding-compatible alternative is available, switching is usually preferable, particularly in early lactation or when high or chronic doses are envisaged.breastfeedingnetwork+2
In situations where methylscopolamine is judged necessary, coordination between prescriber, lactation consultant, and pediatrician helps individualize risk management.kellymom+2